Matthias Ernst

Summary

Publications

  1. Thilakasiri P, Huynh J, Poh A, Tan C, Nero T, Tran K, et al. Repurposing the selective estrogen receptor modulator bazedoxifene to suppress gastrointestinal cancer growth. EMBO Mol Med. 2019;11: pubmed publisher
    ..Our findings provide compelling proof of concept to support the repurposing of bazedoxifene for the treatment of gastrointestinal cancers in which IL11 plays a tumor-promoting role. ..
  2. Eissmann M, Dijkstra C, Wouters M, Baloyan D, Mouradov D, Nguyen P, et al. Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ-Dependent Manner. Cancer Immunol Res. 2018;6:409-421 pubmed publisher
    ..Collectively, our data reveal that IL33 functions as a tumor suppressor in sporadic colon cancer. Cancer Immunol Res; 6(4); 409-21. ©2018 AACR. ..
  3. Huynh J, Chand A, Gough D, Ernst M. Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer. 2019;19:82-96 pubmed publisher
  4. Ernst M, Putoczki T. IL-17 cuts to the chase in colon cancer. Immunity. 2014;41:880-2 pubmed publisher
    ..In this issue of Immunity, Wang et al. (2014) now demonstrate that IL-17A receptors on the intestinal epithelium promote progression of APC mutant adenomas associated with IL-6 expression and that IL-17A confers chemotherapy resistance. ..
  5. Johnstone C, Chand A, Putoczki T, Ernst M. Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer. Cytokine Growth Factor Rev. 2015;26:489-98 pubmed publisher
    ..We review current strategies to interfere with IL-11 signaling and advocate that inhibition of IL-11 signaling may represent an emerging therapeutic opportunity for numerous cancers. ..
  6. Thiem S, Eissmann M, Elzer J, Jonas A, Putoczki T, Poh A, et al. Stomach-Specific Activation of Oncogenic KRAS and STAT3-Dependent Inflammation Cooperatively Promote Gastric Tumorigenesis in a Preclinical Model. Cancer Res. 2016;76:2277-87 pubmed publisher
    ..Cancer Res; 76(8); 2277-87. ©2016 AACR. ..
  7. Huynh J, Etemadi N, Hollande F, Ernst M, Buchert M. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies. Semin Cancer Biol. 2017;45:13-22 pubmed publisher
    ..Here we provide an update on novel insights into the role of STAT3 in immune suppression and describe current therapeutic strategies that target the JAK/STAT3 signaling axis for the treatment of malignancies. ..
  8. Poh A, Love C, Masson F, Preaudet A, Tsui C, Whitehead L, et al. Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression. Cancer Cell. 2017;31:563-575.e5 pubmed publisher
    ..Thus, Hck may serve as a promising therapeutic target for solid malignancies. ..